QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NYSE:CNMD

CONMED (CNMD) Competitors

$131.68
+3.59 (+2.80%)
(As of 06/8/2023 ET)
Compare
Today's Range
$127.30
$133.13
50-Day Range
$114.11
$128.18
52-Week Range
$71.09
$133.13
Volume
603,849 shs
Average Volume
389,195 shs
Market Capitalization
$4.03 billion
P/E Ratio
N/A
Dividend Yield
0.61%
Price Target
$130.40

CNMD vs. INMD, ITGR, TMDX, LIVN, OM, BLFS, MASI, ACAD, ARWR, and PGNY

Should you be buying CONMED stock or one of its competitors? The main competitors of CONMED include InMode (INMD), Integer (ITGR), TransMedics Group (TMDX), LivaNova (LIVN), Outset Medical (OM), BioLife Solutions (BLFS), Masimo (MASI), ACADIA Pharmaceuticals (ACAD), Arrowhead Pharmaceuticals (ARWR), and Progyny (PGNY). These companies are all part of the "medical" sector.

CONMED vs.

CONMED (NYSE:CNMD) and InMode (NASDAQ:INMD) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking.

55.2% of InMode shares are held by institutional investors. 7.6% of CONMED shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CONMED currently has a consensus target price of $130.40, suggesting a potential downside of 0.97%. InMode has a consensus target price of $45.71, suggesting a potential upside of 33.78%. Given InMode's stronger consensus rating and higher possible upside, analysts plainly believe InMode is more favorable than CONMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CONMED
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
InMode
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

InMode has a net margin of 36.05% compared to CONMED's net margin of -8.53%. InMode's return on equity of 36.35% beat CONMED's return on equity.

Company Net Margins Return on Equity Return on Assets
CONMED -8.53% 11.38% 3.66%
InMode 36.05% 36.35% 31.88%

In the previous week, InMode had 1 more articles in the media than CONMED. MarketBeat recorded 6 mentions for InMode and 5 mentions for CONMED. InMode's average media sentiment score of 1.19 beat CONMED's score of 0.70 indicating that InMode is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CONMED
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
InMode
5 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

CONMED has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, InMode has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500.

InMode received 137 more outperform votes than CONMED when rated by MarketBeat users. Likewise, 77.84% of users gave InMode an outperform vote while only 43.75% of users gave CONMED an outperform vote.

CompanyUnderperformOutperform
CONMEDOutperform Votes
14
43.75%
Underperform Votes
18
56.25%
InModeOutperform Votes
151
77.84%
Underperform Votes
43
22.16%

InMode has lower revenue, but higher earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$1.05 billion3.85-$80.58 million-$3.25-40.52
InMode$454.27 million6.24$161.52 million$2.0116.97

Summary

InMode beats CONMED on 16 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNMD vs. The Competition

MetricCONMEDElectromedical equipment IndustryMedical SectorNYSE Exchange
Market Cap$4.03B$3.43B$4.59B$15.01B
Dividend Yield0.63%1.56%2.37%3.93%
P/E Ratio-40.528.4098.8919.30
Price / Sales3.8558.053,427.738.97
Price / Cash24.2715.1391.1923.77
Price / Book5.386.084.717.35
Net Income-$80.58M$86.83M$117.69M$901.21M
7 Day Performance6.31%1.54%2.69%5.27%
1 Month Performance7.29%-2.04%2.03%4.90%
1 Year PerformanceN/A21.48%11.36%-6.19%

CONMED Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INMD
InMode
2.3573 of 5 stars
$34.56
+1.3%
$45.71
+32.3%
+31.6%$2.83B$474.42M17.19362Positive News
ITGR
Integer
1.8164 of 5 stars
$83.25
+0.7%
$88.67
+6.5%
+9.8%$2.77B$1.38B41.0110,000Analyst Revision
Positive News
TMDX
TransMedics Group
1.271 of 5 stars
$79.40
+6.2%
$72.29
-9.0%
+182.5%$2.58B$93.46M-83.58148Insider Selling
News Coverage
High Trading Volume
LIVN
LivaNova
2.417 of 5 stars
$47.05
+1.5%
$64.60
+37.3%
-32.6%$2.53B$1.02B-30.552,900
OM
Outset Medical
0.9286 of 5 stars
$22.93
+6.1%
$24.50
+6.8%
+1.3%$1.13B$115.38M-6.50444
BLFS
BioLife Solutions
1.7162 of 5 stars
$24.08
+1.7%
$28.00
+16.3%
+60.2%$1.05B$161.76M-7.06432
MASI
Masimo
2.5853 of 5 stars
$166.18
+0.9%
$188.88
+13.7%
+16.2%$8.77B$2.30B76.236,000
ACAD
ACADIA Pharmaceuticals
1.7695 of 5 stars
$23.99
+0.1%
$25.43
+6.0%
+34.8%$3.90B$517.23M-26.36514
ARWR
Arrowhead Pharmaceuticals
2.1934 of 5 stars
$36.12
+3.2%
$58.08
+60.8%
+4.5%$3.86B$272.80M-25.26329
PGNY
Progyny
2.4111 of 5 stars
$41.38
+3.1%
$48.86
+18.1%
+32.9%$3.91B$786.91M96.23311Insider Selling

Related Companies and Tools

This page (NYSE:CNMD) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -